Regencell Bioscience is working on TCM opportunities, but what exactly is TCM?

Precision BioSciences (NASDAQ:DTIL) shares rose 13% Monday following the FDA’s Fast Track designation for PBGENE-DMD, its gene editing therapy for Duchenne muscular dystrophy. The Fast Track ...

NovaBridge Biosciences NBP shares are up on Monday following the announcement of positive topline results from the Phase 2a study of VIS-101, a treatment for retinal vascular diseases. Trial Data The ...

I wouldn't touch Regencell with a 10-foot pole because of the high risks involved in the business. That includes the lack of a product, the focus on TCM, and the very nature of the early stage ...

Solid Biosciences Inc. (NASDAQ:SLDB) shares rose 14% after the company announced an oversubscribed $240 million private placement with institutional investors. Th ...

Arcus Biosciences beat FY25 EPS/revenue estimates as Casdatifan drives upside; $1.01B cash funds Phase 3 into 2H28. Click for ...

Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: ...

South Korea's Hyundai Bioscience said Friday it has joined a global clinical trial in Vietnam for dengue fever, a mosquito-borne viral disease.

Regencell looks like a rather speculative bet, and investors should look elsewhere, for instance, toward a well-established ...

Q4 2025 earnings call: revenue, margins, 2026 growth guidance, Niagen Plus injection kits, telehealth plans & FDA lawsuit—read now.

First Turn Management acquired 824,283 shares of Cogent Biosciences in the fourth quarter. The quarter-end value for the new stake rose by $29.28 million, reflecting both trading activity and price ...

Forte Biosciences, Inc. ( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with ...